Real-world outcomes of FOLFIRINOX versus gemcitabine plus nab-paclitaxel and prognostic factors in advanced pancreatic cancer: a retrospective cohort study
Therapeutic Advances in Medical Oncology · 2026-06 · 18
DOI: 10.1177/17588359261456797 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 18.06.2026. Verfasst von Carlos Escriva-Aranda und 10 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Hospital Universitario y Politécnico La Fe, Avenida Fernando Abril Martorell Nº 106, Valencia 46026, Spain. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
FOLFIRINOX (FFX) and gemcitabine plus nab-paclitaxel (GnP) are the main first-line regimens for advanced pancreatic adenocarcinoma. No randomized clinical trials have directly compared their efficacy, and real-world data remain limited.
Objectives
The primary endpoint of this study was to compare overall survival (OS) and progression-free survival (PFS) between the two regimens. Secondary endpoints included the objective response rate (ORR) and the identification of prognostic factors.
Design
Retrospective, single-center cohort study.
Methods
Patients with locally advanced or metastatic pancreatic adenocarcinoma treated with first-line FFX or GnP at a tertiary referral center in Spain between 2011 and 2024 were included. OS and PFS were estimated using the Kaplan–Meier method and compared with the log-rank test. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using Cox proportional hazard models. Propensity score matching was performed as a sensitivity analysis.
Results
A total of 200 patients were analyzed (FFX, n = 42; GnP, n = 158). Median OS was 10.6 months (95% CI 8.0–14.3) for FFX and 9.6 months (95% CI 8.4–11.6) for GnP (HR 1.05, 95% CI 0.74–1.50; p = 0.78). Median PFS was 5.19 months (95% CI 3.12–8.64) and 4.63 months (95% CI 3.61–5.72), respectively (HR 1.09, 95% CI 0.77–1.54; p = 0.64). ORR was 44.2% for FFX and 29.1% for GnP ( p = 0.063). Independent prognostic factors for OS included Eastern Cooperative Oncology Group performance status ⩾2, elevated neutrophil-to-lymphocyte ratio, lactate dehydrogenase, and CA 19-9 levels. Propensity score-matched analysis confirmed comparable OS and PFS between groups.
Conclusion
In this real-world cohort, FFX and GnP were associated with similar OS and PFS outcomes. The retrospective design and baseline imbalances between groups limit causal inference due to potential residual confounding and selection bias.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical Oncology Department, Hospital Universitario y Politécnico La Fe, Avenida Fernando Abril Martorell Nº 106, Valencia 46026, Spain.
- Pathology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
- Medical Oncology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
ORCID-Profile: Carlos Escriva-Aranda, Elisa Gómez Roch, Patricia Capdevila
Zitieren
APA
Escriva-Aranda, C., Giner-Moreno, E., Soria Hernández, E., Esteve Gallego, J., Gómez Roch, E., Capdevila, P., Carrasco Picazo, C., Ortiz Gracia, A., Vidal Jiménez, D., Aparicio, J., & Díaz Beveridge, R. (2026). Real-world outcomes of FOLFIRINOX versus gemcitabine plus nab-paclitaxel and prognostic factors in advanced pancreatic cancer: a retrospective cohort study. Therapeutic Advances in Medical Oncology, 18. https://doi.org/10.1177/17588359261456797
Vancouver
Escriva-Aranda C, Giner-Moreno E, Soria Hernández E, Esteve Gallego J, Gómez Roch E, Capdevila P, et al. Real-world outcomes of FOLFIRINOX versus gemcitabine plus nab-paclitaxel and prognostic factors in advanced pancreatic cancer: a retrospective cohort study. Therapeutic Advances in Medical Oncology. 2026;18. doi:10.1177/17588359261456797
BibTeX
@article{EscrivaAranda2026,
author = {Escriva-Aranda, Carlos and Giner-Moreno, Eduardo and Soria Hernández, Emilio and Esteve Gallego, Josep and Gómez Roch, Elisa and Capdevila, Patricia and Carrasco Picazo, Cristobal and Ortiz Gracia, Alba and Vidal Jiménez, Daniel and Aparicio, Jorge and Díaz Beveridge, Robert},
title = {Real-world outcomes of FOLFIRINOX versus gemcitabine plus nab-paclitaxel and prognostic factors in advanced pancreatic cancer: a retrospective cohort study},
journal = {Therapeutic Advances in Medical Oncology},
year = {2026},
volume = {18},
doi = {10.1177/17588359261456797}
}
EUVIMED